Intellia Therapeutics NTLA is gearing up to announce its quarterly earnings on Thursday, 2024-11-07. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Intellia Therapeutics will report an earnings per share (EPS) of $-1.38.
Investors in Intellia Therapeutics are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
Performance in Previous Earnings
In the previous earnings release, the company missed EPS by $0.29, leading to a 4.11% drop in the share price the following trading session.
Here's a look at Intellia Therapeutics's past performance and the resulting price change:
| Quarter | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| EPS Estimate | -1.23 | -1.38 | -1.45 | -1.50 |
| EPS Actual | -1.52 | -1.12 | -1.46 | -1.38 |
| Price Change % | -4.0% | -2.0% | -4.0% | -3.0% |
Stock Performance
Shares of Intellia Therapeutics were trading at $15.43 as of November 05. Over the last 52-week period, shares are down 37.16%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release.
To track all earnings releases for Intellia Therapeutics visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
